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The utilization of mathematical modeling and simulation in drug development
encompasses multiple mathematical techniques and the location of a drug candidate
in the development pipeline. Historically speaking they have been used to analyze
experimental data (i.e., Hill equation) and clarify the involved physical and chemical
processes (i.e., Fick laws and drug molecule diffusion). In recent years the advanced
utilization of mathematical modeling has been an important part of the regulatory review
process. Physiologically based pharmacokinetic (PBPK) models identify the need to
conduct specific clinical studies, suggest specific study designs and propose appropriate
labeling language. Their application allows the evaluation of the influence of intrinsic
(e.g., age, gender, genetics, disease) and extrinsic [e.g., dosing schedule, drug-drug
interactions (DDIs)] factors, alone or in combinations, on drug exposure and therefore
provides accurate population assessment. A similar pathway has been taken for the
assessment of drug safety with cardiac safety being one the most advanced examples.
Mechanistic mathematical model-informed safety evaluation, with a focus on drug
potential for causing arrhythmias, is now discussed as an element of the Comprehensive
in vitro Proarrhythmia Assay. One of the pillars of this paradigm is the use of an in silico
model of the adult human ventricular cardiomyocyte to integrate in vitro measured data.
Existing examples (in vitro—in vivo extrapolation with the use of PBPK models) suggest
that deterministic, epidemiological and clinical data based variability models can be
merged with the mechanistic models describing human physiology. There are other
methods available, based on the stochastic approach and on population of models
generated by randomly assigning specific parameter values (ionic current conductance
and kinetic) and further pruning. Both approaches are briefly characterized in this
manuscript, in parallel with the drug-specific variability.
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INTRODUCTION
Mechanistic Modeling and Simulation Approach in the Process of
Drug Development in Light of the Recent Changes to
FDA/EMA/PMDA Regulations
The mathematical modeling and simulation (M&S) approach has held its place in the drug
development process since the very beginning. Havingmoved from academic curiosity to industrial
practice the approach is used to both analyze the data and understand the physical mechanisms
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involved. Model-informed drug development (MIDD) is here to
stay and it also has been recently indicated as one of the major
areas of scientific priority by the regulators (Huang et al., 2013;
Zineh et al., 2017). Initially, the outcome of pharmacometric
analyses has impacted the decision making process of drug
development (Miller et al., 2005; Lee et al., 2011). In recent
years regulatory support for mechanistic physiological modeling
has helped to bridge the gap between preclinical and clinical
observations with respect to understanding biological systems
(Rowland et al., 2015; Friedrich, 2016).
Special interest has been given to physiologically based
pharmacokinetic (PBPK) modeling defined by WHO as
“quantitative descriptions of the absorption, distribution,
metabolism, and excretion (ADME) of chemicals in biota based
on interrelationships among key physiological, biochemical
and physicochemical determinants of these processes”1. A
physiologically based pharmacokinetic approach is based on
a combination of the physiology, environment, and drug
specific information. These parameters are further utilized
in the mechanistic models describing the pharmacokinetics
(PK) and/or pharmacodynamics (PD) of a drug(s) of interest
(Rostami-Hodjegan, 2012). This is not a new concept and it is
suggested that the roots of PBPKmodels originate from the work
of Teorell, published in 1937 (Teorell, 1937). Recent scientific
advances and the development of models utilizing PBPK
scaffolding are invaluable in the situation where clinical trials are
extremely challenging or impossible. This includes specialized
populations and situations of special interest such as pregnant
woman and pediatric applications (Lu et al., 2012; Abduljalil
et al., 2014). PBPK models are utilized for various applications
throughout a drug’s life cycle. Results of their simulations can
be used to support the planning of specialized clinical studies,
support dosing recommendations and the labeling of products
(Zhao et al., 2011; Jones et al., 2015; Shepard et al., 2015; Wagner
et al., 2015). The simulation results are used in lieu of conducting
clinical studies or provide information that otherwise would
have been missing in some specific situations (Jamei, 2016).
The use of PBPK modeling was included in the guidance
documents for industry provided by the U.S. Food and Drug
Administration (FDA), the European Medicines Agency (EMA)
and theMinistry of Health Labor andWelfare (MHLW) of Japan.
The latter, namely the draft of the drug interaction guideline for
drug development and labeling recommendations published by
the Japanese Ministry of Health, Labor and Welfare in 2014,
suggested the PBPK application in the assessment of drug-
drug interaction (DDI; Saito et al., 2014). Recent guidelines
published by the FDA and EMA list several points in the drug
development process where PBPK modeling may be applicable
in order to support decisions in the premarketing, as well as
at postmarketing, stage2,3. PBPK analyses are currently widely
accepted and used not only as a research tool but also to
1www.who.int/ipcs/methods/harmonization/areas/pbpk/en/
2www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2016/
07/WC500211315.pdf
3www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/
Guidances/UCM531207.pdf
support drug registration applications including investigational
new drugs (INDs), new drug applications (NDAs), biologics
license applications (BLAs), or abbreviated new drug applications
(ANDAs; Sato et al., 2017). As of December 2016 there were
36 approved drugs, which provided PBPK M&S results, in the
U.S. new drug application labeling procedure. In addition to
PBPK, the Advisory Committee mentioned mechanistic safety
modeling, particularly, risk prediction/assessment as a promising
MIDD area4.
It is highly likely that the next application for PBPK
models is in the area of precision dosing and personalized
medicine (Hartmanshenn et al., 2016). This is achievable due
to the specific structure of the physiologically-based models,
where system description is clearly separated from the drug
and external parameters (i.e., dosing schema). The biological
parameters are described by large collections of anatomical
and physiological data derived from literature or existing
databases. For the assessment of inter- and to some degree intra-
individual variability, virtual individuals, and virtual populations
are randomly created (Jamei et al., 2009a).
In Vitro—in Vivo Extrapolation (IVIVE) as an
Approach
In vitro—in vivo extrapolation (IVIVE) as a phrase
covers all techniques utilized for the prediction of human
pharmacokinetics and pharmacodynamics based on the ADME
information ADME in addition to drug activity and toxicity.
It is crucial to mention that, in principle, the data comes from
the in vitro studies, where various models and techniques are
utilized. The main challenge is to translate the data, often
heterogeneous, from the level of a “Petri dish” to the complex
system of the human body. Therefore, what is needed are in vitro
methods mimicking basic phenomena occurring in a human
body at the cellular or subcellular level, and models describing
the human body as a biological system. The latter describing
models of human organs, tissues, or the whole body include the
incorporation of the above mentioned PBPK systems. There are
other approaches currently implemented, which combine and
merge traditional compartmental models and various systems
biology models, to describe biochemical and physiological
phenomena (Sorger et al., 2011). It’s worth adding that the
addition of available human in vivo data enriches the model and
can improve the degree of predictability (Tsamandouras et al.,
2015). Practical utilization of the IVIVE concept, with the use of
PBPK models and population data, covers various populations
from healthy individuals up to the special populations (e.g.,
diseased—renal insufficiency, cirrhosis etc.) and pediatric
populations (Sager et al., 2015).
Interestingly, conceptually similar approaches were
independently introduced in the pharmacokinetics and
pharmacodynamics area (Visser et al., 2014). The biophysically
detailed models describing cell electrophysiology can be used
for the in vitro—in vivo extrapolation, as proposed in the CiPA
4www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/
Drugs/AdvisoryCommitteeforPharmaceuticalScienceandClinicalPharmacology/
UCM544838.pdf
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(Comprehensive in vitro Proarrhythmia Assay) initiative, as
described below (O’Hara et al., 2011; Gintant et al., 2016). There
is although one difference between the IVIVE/PBPK approach
and the proposed IVIVE/safety approach. The latter, namely
safety in vitro—in vivo extrapolation, has so far been done with
the use of models describing cell electrophysiology without
accounting for variability.
CiPA Initiative—What Does It Change,
Where We Are, and What Is Potentially
Lacking
Regardless of the opinion on the current changes—whether it is
a logical consequence of the evolutionary changes or Copernican
Revolution—we are witnessing a significant paradigm shift in the
area of drug cardiac safety assessment. The recently proposed
CiPA schema for the preclinical evaluation of proarrhythmic
liabilities proposes to assess proarrhythmic risk based on
in silico reconstructions of human ventricular electrical activity.
A biophysically detailed model aims to analyze repolarization
abnormalities such as EADs. The input information includes
in vitro measured data on the drug concentration-dependent
inhibition of multiple human cardiac currents (Colatsky et al.,
2016; Gintant et al., 2016). The O’Hara-Rudy (ORd) model
was chosen as the starting point for developing an in silico
model with the ultimate aim of providing a system suitable for
regulatory decision making (O’Hara et al., 2011). The model is
being further developed by the addition of a more mechanistic
description of drug-channel binding kinetics (Li et al., 2017). The
model proposes to generate output allowing for the separation
of the reference drugs into three distinct risk categories—low,
intermediate and high risk. The validation is planned to be
performed with the use of 28 (12) drugs as detailed in the report
presented at the FDA Briefing Document Pharmaceutical Science
and Clinical Pharmacology Advisory Committee Meeting March
15, 2017 Topic: Strategies, approaches, and challenges in model-
informed drug development (MIDD). According to the FDA’s
suggested strategy, estimation of the inter-individual variability
in a drug’s pharmacokinetics and pharmacodynamics is a key
issue in recent drug development. PBPK modeling addresses
this issue and so should mechanistic safety modeling. In PBPK,
the variability in PK prediction is assured by specifying the
population-dependent distribution of parameters’ values and
the covariation between these parameters (Jones et al., 2015).
Regarding cardiac risk assessment, the variability is already
observed at the stage of in vitro measurements, e.g., in drug
effects on the ventricular ion currents or in the effects on
human stem cell-derived cardiomyocytes (iPSC-CM) which
differ in channel gene expression profiles and patterns of
arrhythmic events after testing with the same model drug
(Elkins et al., 2013; Blinova et al., 2017). The observational
uncertainty together with other sources of uncertainty influence
computational model inputs, and consequently, the confidence
of the output, regardless of the electrophysiological model used
(Johnstone et al., 2016; Mirams et al., 2016). The frequently used
cardiac models do not account for physiological or experimental
variation in their default parametrization (Davies et al., 2016).
However, clinical observations leave no doubts that variability
is important, and drug-independent factors may play a crucial
role in triggering a drug cardiac effect. The analyses of case
reports of QT interval prolongation and ventricular arrhythmia,
associated with cisapride, revealed that often in the case of these
adverse events the patients had more than one contraindication
that predisposed them to arrhythmia. The drug was therefore
withdrawn from the U.S. market in 2000 (Wysowski et al., 2001).
The coincidence of multiple risk factors, both physiological and
pathophysiological was also the case for TdP induction after the
administration of certain drugs, e.g., erythromycin (Hancox et al.,
2014), quetiapine (Hasnain et al., 2014), methadone (Vieweg
et al., 2013b), and risperidone (Vieweg et al., 2013a). These
are all exemplary drugs which are known to pose the risk of
TdP according to the Credible Meds classification and are at
the same time safely used if taken properly5. The observed
variability in the PD response may come from the drug itself,
since for some compounds the QTc interval prolongation is said
to be dose or concentration-related (Krantz et al., 2003; Fanoe
et al., 2009). However, even then the variation in individual
QTc length cannot be explained solely by PK and factors that
affect the ADME processes. There are examples illustrating the
lack of correlation between electrophysiological changes and
drug plasma concentrations (Wiśniowska et al., 2016). Even
in healthy subjects the observed QTc changes, following drug
administration, may vary by about 80 ms (Jerling and Abdallah,
2005; Hulhoven et al., 2008) as age, sex, and race are said to
affect cardiac electrophysiology (Macfarlane et al., 1994) not
to mention observed circadian intra-subject variations (Molnar
et al., 1996).
There are also special populations that should be considered
when assessing drug triggered cardiac effects. First of all, the
cardiac action potential is affected in patients with cardiac
channelopathies associated with genetic mutations. One of the
main congenital phenotypes is long QT syndrome (LQTS)
which is prevalent in 1:3,000–1:5,000 in the general population
(Goldenberg and Moss, 2008) manifesting with a QTc length of
above 460 ms (Abriel and Zaklyazminskaya, 2013). The most
frequent mutations that are responsible for congenital LQTS
were found in genes that code for proteins in the potassium hERG
channel (KCNQ1 and KCNH2) and the Nav1.5 sodium channel
(SCN5A; Bohnen et al., 2016). The LQTS patients are said to be
particularly vulnerable to drug-related arrhythmias (Goldenberg
et al., 2008). Also, comorbidities were found to contribute to
QTc-prolongation. The analysis conducted by Vandael et al.
(2017) revealed strong evidence for ischemic cardiomyopathy,
hypertension, arrhythmia, and thyroid disturbances to be risk
factors contributing to QTc interval prolongation.
Variability in Cardiac Models—Stochastic
vs. Deterministic Approach
Mathematical models of cardiac cell electrophysiology have
proved their value and now hold an established position in
research and drug development (Amanfu and Saucerman, 2011;
Davies et al., 2016). It all began with the work of Hodgkin and
5https://crediblemeds.org/
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Huxley where they modeled the cell membrane as a capacitor
with batteries and resistors and described its electrophysiological
behavior (Hodgkin and Huxley, 1952). The following ordinary
differential equation was established:
dV
dt
=
Iion − Istim
Cm
,
where V is voltage, t is time, Iion is the sum of all transmembrane
ionic currents, Istim is the externally applied stimulus current,
and Cm is cell capacitance of the membrane per unit surface area
(Ten Tusscher and Panfilov, 2006). Beginning from the relatively
simple Noble’s model (Noble, 1962), cardiac electrophysiology
models have evolved tremendously, and now include a detailed
description on cardiac ion channels, pumps and transporters,
as well as intracellular calcium handling (Noble, 2007; Fink
et al., 2011). The models proved successful for studying
cardiac physiology and understanding pathological changes (e.g.,
arrhythmias) associated with diseases over the last decades and
currently they are used in the safety assessment of drugs (Mirams
et al., 2012; Roberts et al., 2012; Davies et al., 2016; Gintant
et al., 2016). To be a vital element of the safety-related decisions
made through the various stages of drug development and in
the clinic, the models have to ascertain credibility, i.e., properly
reproduce the electrophysiology of a population and individual
patients. The question arises asking if it is feasible to use a
single traditional cardiac model with input parameters being
the mean values, averaged across many subjects, and generating
an output as a single value, thus presenting behavior a of
“representative” cell. Until recently there wasn’t much interest in
the variability in the field of cardiac electrophysiology modeling.
Several approaches have now been proposed, and implemented,
to introduce variability into cardiac models and account for
inter- and intra-patients differences. All of the approaches stem
from the belief that the “average patient” does not exist and
a traditional model cannot accurately explain the observed
differences between patients.
Stochastic Approach
Physiological variability can be investigated and modeled by
constructing populations of experimentally calibrated models.
This approach has been introduced a while ago and is further
developed by researchers from various organizations including,
but not limited to, the Department of Pharmacology and Systems
Therapeutics, Mount Sinai School of Medicine, New York (Sobie,
2009; Sarkar et al., 2012), the Department of Computer Sciences
at Oxford University (Britton et al., 2013; Sánchez et al., 2014;
Muszkiewicz et al., 2016; Pueyo et al., 2016; Zhou et al., 2016),
and other (Marder and Taylor, 2011). Variability in a model’s
behavior is accomplished by the multiplication of its parameter
values by sampled scaling factors, which results in an ensemble
of possible outputs instead of an average one. Once the baseline
model (appropriate for the research question) is selected, the
parameters of variation have to be chosen, and the ranges for
parameter sampling need to be defined. Both depend on the
study aim and the target population (e.g., healthy, diseased) to
be investigated.
There are multiple approaches available for generating the
population of models. For example, parameters and their ranges
generate high-dimensional spaces from which their values are
sampled using different sampling algorithms (e.g., the Latin
Hypercube, Monte Carlo method) to generate an ensemble of
variant models (Drovandi et al., 2016). The candidate models
are simulated to mimic, for example, experimental settings
regarding bath solution composition, voltage protocol, and
pacing rate. The pool of models is pruned according to the
boundaries for a range of permitted model outputs, defined by
minimal and maximal values observed in the experiment. Such
calibration yields the experimentally-calibrated populations of
models presenting electrophysiological behavior that reproduce
the results of experiments which can be further analyzed for the
parameters underlying the observed response variability (Britton
et al., 2013). The model could also be employed to assess a range
of responses across the population under certain conditions,
e.g., diseased, or reflecting drug application (Muszkiewicz et al.,
2016).
The other approach is based on parameter sensitivity analysis
techniques which can be applied to generate quantitative
predictions based on considering behaviors within a population
of models (Romero et al., 2009). In the single parameter scanning
one can increase or decrease the parameter of interest, run
simulation and save the simulation results. Such procedure can
be performed for multiple parameters, with the use of various
techniques and the outcome is expressed in a quantitative
manner. Sobie and colleagues have also utilized more complex
procedures and varied all parameters at once (Sarkar and
Sobie, 2010, 2011). Assuming that the endpoint of interest is
dichotomous in nature (i.e., EAD occurence)Morotti and Grandi
proposed technique based on the multivariate logistic regression
analysis, allowing for sensitivity analysis and investigating factors
influencing the endpoint occurrence at the same time (Morotti
and Grandi, 2016).
The methodology applied to experimentally-calibrated
populations of models can be regarded as the refinement and
extension of the sensitivity analysis method and populations
of models constructed without a calibration step. In the latter
two, values of single or multiple parameters are varied in a
predefined range, while allowable values of model outputs
are not constrained with experimental data thus may not be
representative for certain subject groups. All of thesemodels offer
valuable insights into sources of variability and the pathological
background of different heart conditions. Moreover, they allow
the assessment of not only the average drug effect on cardiac
electrophysiology, but also allow the screening of drug effects
across a certain population. They, however, cannot be employed
to evaluate the risk of an individual patient who is to be treated
with a certain drug. This is because most variability sources
considered by the model (e.g., ion channels conductance, gating
kinetics, densities, resting membrane potential, membrane
potential, upstroke velocity) are factors whose values cannot
be determined for the particular patient. Another problem
is the requirement to define the cut off threshold for non-
physiological simulation results, since such a decision is always
arbitrary.
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Deterministic Approach
The other approach is based on the observation and description
of the biological parameters characterizing the system of interest,
in this case the human organism. Data describing demographic,
genetic, anatomical, and physiological factors are collected and
analyzed to describe the distribution of the parameter in a
population and allow constructing its virtual counterpart instead
of an average patient. Also some of those factors can be correlated
with the parameters of a cardiomyocyte model, e.g., age and
the cardiomyocyte volume and area (Polak et al., 2012). The
main data sources remain the published scientific reports and
clinical databases (ICRP, 2002; Valentin, 2003). This approach
allows for differentiation between different populations; both
healthy (e.g., considering ethnicity) and diseased (e.g., obese,
renally impaired, diabetic), or of special interest (e.g., pregnant
women, pediatric population; Jamei et al., 2009b). Equations
describing the distribution of the system parameters for the PBPK
model are derived from the distributions of data based on real
populations and patients. Additionally, such an approach takes
into account the dynamic changes observed with the parameter
of choice (e.g., circadian changes of heart rate). An application
includes the ontogeny description and age dependent variation
of the chosen parameters (Salem et al., 2013). What is also of
importance is the option to define the inter-correlation between
various parameters. A virtual population can be generated from
values and formulae describing demographic, anatomical, and
physiological variables using a correlated Monte Carlo approach
which protects from the non-physiological combinations of the
model parameters (e.g., kidney size and liver size). This allows
the prediction of variability before the clinical study phase, in
contrast to a statistical approach (e.g., population PK analysis),
which requires prior clinical data to characterize variability.
Additionally it allows for the clear separation of information
on the system (i.e., human body) from that of the drug (e.g.,
physicochemical characteristics), and the environment (e.g.,
dose, concomitant drugs).
It is obvious that the model prediction will depend on the
quality of the gathered data, correctness of the analysis, and
appropriateness of the conclusions drawn from the distribution
of the parameters. Therefore, the criteria of inclusion and
exclusion for the reports and papers (in addition to certain
values) have to be defined prior to the commencement of the data
collection process. The same applies to the statistical analysis, and
all methods and tools.
There are multiple biological parameters influencing the
ECG and its behavior. From a biological perspective, factors
influencing cardiac electrophysiology can be classified into one
of three key groups: (i) demography; (ii) anatomy, and/or
physiology; and (iii) genetics. Examples of the most important
parameters are listed below:
(i) Demography—age, gender
(ii) Anatomy and/or physiology—plasma ions concentrations
(K+, Ca2+), cardiomyocyte size (volume, area),
cell electric capacitance, heart wall thickness,
heterogeneity of cells across heart wall, heart rate, sex
hormones
(iii) Genetics—common polymorphisms and mutations at the
level of ion channels/pumps/exchangers
For some of the above mentioned parameters statistical
models describing their distribution in the population were
developed based on the available data. This includes relationship
between age, human left ventricle cardiomyocyte volume,
and electric capacitance (Polak et al., 2012), left ventricular
heart wall thickness (Fijorek et al., 2014a), or plasma ions
concentration (Fijorek et al., 2014b). The latter, namely plasma
ions concentration, together with the heart rate follow the
circadian variability (Massin et al., 2000; Sennels et al., 2012).
Such time of the day dependent variation influences the
ECG and the parameters including QT (Karjalainen et al.,
1994). Therefore, models describing the diurnal variability of
such crucial parameters are also being developed and utilized
(Fijorek et al., 2013a,b). They are also included in the virtual
population generators, which build the virtual individuals being
exposed to the drug in the in silico conditions (Mishra et al.,
2014; Wiśniowska and Polak, 2016). The main limitation of
this method is the limited amount of data available for the
model building and information relating to the inter-correlation
between parameters.
It is undisputable that sources of variability identified and
already incorporated into in silico models cannot explain the
whole observable inter- and intra-individual variability. The
question is if it is already sufficient to provide reliable predictions.
Drugs-Specific Variability
In the model-based drug safety assessment, apart from system-
dependent variability, there is also another source of variability
(or rather uncertainty) introduced into the model. The effects
caused by exposure to a drug are modeled as concentration-
dependent changes of ion currents known to be affected by the
drug. The drug-channel interaction is quantified experimentally
by constructing a Hill plot characterized by IC50 and the Hill
coefficient value. There is no standardized protocol for drug-
triggered ion channel block measurement, however multiple
cell models and voltage protocols are accepted. This results in
significant discrepancies between IC50 values reported for a
given compound (amiodarone: 0.015–38.3 microM; cisapride:
0.0051–1.6 microM; dofetilide 0.003–25 microM; E4031: 0.001–
15.8 microM; moxifloxacin: 0.93–398.1 microM; propafenone:
0.085–123 microM; to give just a few examples)6. Additional,
uncertainty introduced into in silico models comes from
uncertainty in the Hill coefficients of reported concentration-
inhibition curves, especially when ion channel blocking potency
for a compound is estimated by high-throughput screening
methods (Elkins et al., 2013). Moreover, even the well-controlled
experiments, carefully conducted in the same experimental
settings, generate different results. This can be due to the
measurement errors, intrinsic- and extrinsic-variability between
samples. The subjective selection of IC50 values, which are taken
as inputs into in silico models, may lead to misleading results.
Drug-specific uncertainty is an undesirable type of variability,
6www.tox-database.net
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however infeasible to eliminate. The use of averaged values has
been proposed tominimize drug-specific bias (Elkins et al., 2013).
The question remains how, if possible, average results produced
with different methods and experimental settings.
The situation is even more complex when the aim is to model
a response to a drug in a realistic population where other drug-
related factors like concomitant medicines, compliance, food and
alcohol consumption have to be accounted for since all these
factors can substantially influence the response.
CONCLUSIONS
Drug pro-arrhythmic potency is a function of the intrinsic
characteristics of the chemical structure and external parameters
associated with the drug. The latter, namely external parameters,
includes system-dependent and environment-dependent items.
Therefore, to properly predict and assess the potential risk all
significant elements should be considered. Translation of the
in vitro data to an in vivo situation, e.g., to optimize clinical
trials, requires such an approach. There are at least two ways to
describe the population specific variability, as described above,
and these elements should be accounted for in the in silico based
cardiac safety assessment. On the other hand, the choice of an
assessment method depends on the actual stage of the drug
development cycle. In the early stages, including discovery phase
such complexity is not necessary, but as the compound advances
along the development process, the assessment should be more
detailed and comprehensive.
It is worth noting that the diseased population would probably
require even more parameters, and the variability would be
larger, as compared against healthy individuals. This is because
of the interrelation of parameters directly (e.g., cell volume
and capacitance), and indirectly (e.g., thyroid-related diseases
and fluid-electrolyte balance disruption) influence the heart cells
electrophysiology. Examples of the above-mentioned parameters
and their analysis clude hypertrophic cardiomyopathy (HCM)
of various character (Polak and Fijorek, 2012). It is worth
noting that stochastic approach, based on the virtually simulated
population of models can be used to identify ionic mechanisms
driving electrophysiological abnormalities not only in HCM, but
also atrial fibrillation, and other diseases, accounting for of the
disease specific variability (Liberos et al., 2016; Passini et al.,
2016). Modeling and simulation approach can be also utilized
to analyze the influence of genetic modifications at the level of
ionic channels on the cardiacmyocytes electrophysiology (Glinka
and Polak, 2013). This includes the recently published example
of the population of models optimized to recapitulate clinical
long QT phenotypes (Mann et al., 2016). The detailed discussion
of this element, namely the disease related variability is out of
the current manuscript scope. There is however clear gap in all
current approaches, namely comprehensive, or to be precise—
as comprehensive as possible—parametrization of the disease
of choice, including all known parameters. This would allowed
to simulate population of virtual individuals closely mimicking
those met in the clinical settings. The models usage could be than
extended from the drugs’ safety assessment to the drugs therapy
optimization.
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